PHONE: 517.536.8210
FAX: 517.536.8205


TransPharm Preclinical Solutions TransPharm Preclinical Solutions TransPharm Preclinical Solutions TransPharm Preclinical Solutions


February 2017

A Note from the President January 2017 marked our 9 year anniversary and the close of another great year here at TransPharm. With 17 new clients in 2016, the TransPharm family now spans over 6 continents. As a result of our continued growth, we were able to reach a major milestone in November: a total of $10M in revenue since I founded the company in 2008. Increased demand also allowed us to welcome some new faces to our team – Brianne Fiero (Associate Scientist) in April, and Brittany Dixon (Scientific Writer) and Emily Gilles (Laboratory Technician) in October. 2016 was also a year of physical growth. A 2,100 sq. ft. addition to our facility, including an expanded animal vivarium and a procedure room, was completed in May. This new space contains both a negative pressure room and a positive pressure room, with corresponding bioBUBBLE® enclosures in each, meaning separate, dedicated areas for C. difficile and germ-free work, respectively. The renovations have already proven advantageous to our clients who currently work in the C. difficile therapy development field. Please contact us for more information. Finally, I’d like to extend an open invitation to visit us here at TransPharm. We wouldn’t be celebrating these successes without our clients, and we’d love the opportunity to meet you personally and provide a tour of our facilities. Thank you for your business and we look forward to working with you in the new year. Daniel Ross President & CEO TransPharm Preclinical Solutions                   In the Lab This past summer, six local high school and college students interested in a career in life science participated in TransPharm’s internship program. Each student spent two weeks working on their own model validation project focused on one of the ESKAPE pathogens. These bacteria, listed below, cause the majority of US hospital infections and are increasingly resistant to current antimicrobials.   Enterococcus faecium Staphylococcus aureus Klebsiella pnuemonia Acinetobacter baumannii Pseudomonas aeruginosa Enterobacter species   Thanks to the hard work of these motivated students and historical data, TransPharm now has a validated model for all ESKAPE pathogens, with some pathogens having several models available. Contact us today for quotes or more information....

Read More

December 2014

A note from your President & CEO, Another year has gone by quickly and 2015 is right around the corner. This January marks our seven year anniversary. It is hard to believe that eight years has passed since Pfizer R & D closed its doors in Ann Arbor, Michigan. January 22nd, 2007 marks the announcement day that made all of us wonder what would happen after Pfizer. I was one of the lucky ones that had a plan shortly after the announcement and that plan was founding TransPharm Preclinical Solutions. We incorporated on April 13th 2007, started renovation to the lab in September of that year and opened our doors on January 2nd, 2008. Today we are considered a global leader for Infectious Disease research and have generated more than 6 million in revenue with over 60 clients around the world. TransPharm has never been stronger and we are eager to see what the future holds for us. During the Holidays, we are very thankful to do what we love and even more thankful to you for allowing us to do this important work. Dan Slight Increase in Pricing Starting in January, TransPharm will be increasing the cost of our studies due to increases in costs from some of our suppliers. We expect the increase to be 5% across the board for all studies, but this could vary depending on study design. Studies booked for January that are scheduled in December will remain at the current price structure. Holiday Schedule TransPharm will be closed this month starting around noon on December 24th and reopen on January 5th. All studies must end no later than the 24th with preliminary data following mid day. All mouse orders scheduled for January 5th must be placed before December 24th. No animals will be on site during this closure. Now is the time to get your studies scheduled for...

Read More

June 2014

A note from your President & CEO, I would like to wish a happy summer to all of you. As we move into warmer weather, vacations and outdoor activities seem to fill our days and time to get things done seems to shorten. Towards that end, I will be brief with this newsletter and want to say that TransPharm has finally been awarded PHS registry with the Office of Laboratory Animal Welfare. Briefly, this means that companies receiving grant funds from NIH are now allowed to spend those funds directly with TransPharm Preclinical Solutions. This is a huge milestone for us and I know it will open the doors to many of the smaller companies receiving grant funds. Please see the notice below and use our Assurance # A4707-01 for all future grant applications to the National Institute of Health. Dan As always, please feel free to contact us: Through our website, Our toll free INFECT line, 1-888-88-INFECT Or dial me direct, 1-517-536-8210 Check us out on Facebook Sincerely, Daniel Ross President & CEO TransPharm Preclinical Solutions,...

Read More

March 2014

A note from your President & CEO, At last, I’ve found a few moments to reconnect with our distribution list which is growing every month. TransPharm finished very strong in 2013, recording our second best year. We’ve also picked up some new clients in the last few months and would like to welcome them to the TransPharm family. I’m very proud to say that we have continued to work with a few clients that have been here since we’ve opened. As the saying goes, “Working with us is Contagious”……. Quickly, I would like to address a single question a few of you have about another large project in the works and how it relates to TransPharm and my goals going forward. I was lucky enough to have an opportunity to purchase a piece of history here in the Irish Hills area where I live. The facility is an original Henry Ford Village Industries site built in the late 1930’s. The plot of land it sits on was the first parcel of land deeded in Brooklyn back in 1832. The plan for this facility is to turn it into an Irish themed destination called the Old Irish Mill. It will include a restaurant, pub, café, a park and Michigan’s largest indoor farmer market. We are very excited about this venture and know it will become one of the favorite tourist stops in the area. So what will happen to TransPharm??? Am I leaving??? Who is going to run the show??? Rest assured, nothing will be changing around here any time soon. My role in this new venture is simply the idea and finance guy. I’m currently involved with a lot of the interior demolition and spearheading the general contracting, but that is to get things going in the right direction. I don’t plan to have an active role in the new organizational chart once the facility is up and running. I will likely pass along the progress on this project as it moves forward. Dan TransPharm named Business of the Year Dan Ross, owner of TransPharm Preclinical Solutions in Napoleon, was surprised when he learned his company was being named Business of the Year by the Brooklyn-Irish Hills Chamber of...

Read More

November 2012

President’s Letter: It is hard to believe another year has come and gone, but here we are again. Getting bundled up and trying to stay warm is never easy, but it is hard to beat the beauty of Michigan in the fall season. The picture below was taken in early October just outside the TransPharm facility. We are extremely lucky to be surrounded by 15 acres of trees, a pond and having the Northern property line border on Stoney Lake Creek. Visiting clients are always pleasantly surprised by our location and the country feel of our facility. One client in particular was taken back by the flock of wild turkeys outside our lab window. I was told that he doesn’t get to see that in France. It’s not uncommon to see deer strutting through the grounds or the occasional fox. We truly do have a unique setting and would like to use this opportunity to invite you to come out and visit. I cant guarantee that the wildlife will cooperate and offer you a glimpse, but I can guarantee that you will be impressed with our AAALAC accredited facility, inside and out. Dan   The Next Level During this holiday season, the TransPharm team has been busy brainstorming and researching the possibilities of taking our services to the next level…the next Biosafety Level that is. We’ve met with consultants and engineers concerning the best approach to upgrade our current, state-of-the art facilities to a BSL 3 laboratory. This will provide our clients with even more infection models with which to screen their antimicrobials. Client inquiries into level 3 models have allowed us to formulate a list of top-priority model validations which include: tuberculosis, anthrax, brucellosis and rickettsial diseases. Of course, this would only be the beginning of potential models we could offer to our clients. If you have a request for early validation of a specific model, please don’t hesitate to contact us! Have a wonderful holiday season and we look forward to working with you in 2013. Dr. Santiago R. Lopez Director of Research     Holiday Office Hours: This is a reminder that the TransPharm offices and vivarium will be closed this year starting on December 21st...

Read More

July 2012

President’s Letter: I’m proud to start out this newsletter by letting you know that TransPharm Preclinical Solutions has once again received recommendation for accreditation from the Association for Assessment and Accreditation of Laboratory Animal Care International. AAALAC accreditation is evaluated every three years, with our recent site visit on July 20th. Programs constantly change, along with the regulations in the use of animals in research. AAALAC’s mission is to ensure that all of these changes are in force and the Program Description for our facility is accurate, complete and adhered to. The continued success of our program is directly related to those individuals on our Institutional Animal Care and Use Committee, or IACUC. I would like to personally thank all those individuals. Libby Ziemke, IACUC administrator Marci Peek, Chair Dr. Megan Nowland, attending Veterinarian and Alternate Chair Joanne Zammit, Scientist Dr. Santiago Lopez, Scientist Dan Wymer, Non-Scientist Dr. Jim Mobley, Alternate scientist Adhering to these global standards is what lead to our success three years ago. This continued recommendation for accreditation bodes well for our continued success. To learn more about AAALAC International please visit: Towards our commitment for high quality research, four individuals here at TransPharm have recently taken their respective level of certification through the American Association of Laboratory Animal Science. AALAS offers these nationwide board exams after certain criteria is met by the individual taking the exam. I would like to congratulate: Heidi Richardson, ALAT level Marci Peek, LAT level Libby Ziemke, LATG level Lisa Lazaroff, LATG level To learn more about AALAS please visit Dan Clostridium difficile murine model In an effort to provide our clients with the most robust and effective murine models of infection, TransPharm has adopted a new bacterial spore preparation for our C. difficile-associated disease model. This improved protocol has been thoroughly validated and rigorously compared to our previous procedure. It has surpassed TransPharm’s high standard of scientific excellence (Figures 1-3), much to the satisfaction of our valued clients with whom we’ve had the pleasure of collaborating. So, if your group is in the market for a murine model of C. difficile-associated disease (or any other infectious disease model), there’s no better time to talk with us! Don’t forget...

Read More